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Abstract
Background: In the setting of recurrent events, research studies commonly count only the first occurrence of an
outcome in a subject. However this approach does not correctly reflect the natural history of the disease. The
objective is to jointly identify prognostic factors associated with locoregional recurrences (LRR), contralateral breast
cancer, distant metastases (DM), other primary cancer than breast and breast cancer death and to evaluate the
correlation between these events.
Methods: Patients (n = 919) with a primary invasive breast cancer and treated in a cancer center in South-Western
France with breast-conserving surgery from 1990 to 1994 and followed up to January 2006 were included. Several
types of non-independent events could be observed for the same patient: a LRR, a contralateral breast cancer, DM,
other primary cancer than breast and breast cancer death. Data were analyzed separately and together using a
random-effects survival model.
Results: LRR represent the most frequent type of first failure (14.6%). The risk of any event is higher for young
women (less than 40 years old) and in the first 10 years of follow-up after the surgery. In the combined analysis
histological tumor size, grade, number of positive nodes, progesterone receptor status and treatment combination
are prognostic factors of any event. The results show a significant dependence between these events with a
successively increasing risk of a new event after the first and second event. The risk of developing a new failure is
greatly increased (RR = 4.25; 95%CI: 2.51-7.21) after developing a LRR, but also after developing DM (RR = 3.94; 95%
CI: 2.23-6.96) as compared to patients who did not develop a first event.
Conclusion: We illustrated that the random effects survival model is a more satisfactory method to evaluate the
natural history of a disease with multiple type of events.
Background
Several randomized trials have shown that breast-con-
serving surgery (BCS) plus locoregional radiotherapy is
an appropriate method of primary therapy for the
majority of stage I and II breast cancers and may be
preferable to radical mastectomy because it provides
survival equivalence while conserving the breast [1]. The
main concern for both physicians and patients is
therefore the risk of local or metastatic recurrence in
the conserved breast or in the contralateral breast.
The risk of recurrence (local, locoregional or contralat-
eral), distant metastases (DM) or second primary cancer
after breast cancer and their predicting factors has already
been documented in the literature [2-6]. In most applica-
tions, Cox proportional hazard models are fitted and prog-
nostic factors are studied for each specific event [3]. The
most straightforward approach in these recurrent event
settings is simply to count only the first occurrence of an
outcome in a subject [5]. This analytical strategy is
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cations that can occur if a first event affects either the risk
of subsequent events or compliance with ongoing treat-
ment [7]. However, consideration of only first events is
not satisfactory to evaluate the natural history of a disease
and the effects of therapeutic interventions, furthermore,
this is inefficient because it does not utilize all the available
information. The potential benefits in terms of events pre-
vented by a treatment can be underestimated if only the
first failure is considered.
The solution could be to include as time-dependent
covariates the different intermediate events which may
affect the patient’s event of interest and to study their
prognostic impact [4,8]. Yet, interpretation of these
time-dependent covariates can be difficult in practice. In
this setting of semi-competing risk events, Cox propor-
tional hazard models are simply used for each of the
events [9], yet they are unable to estimate the associa-
tion between these multiple events.
This article hypothesizes that Cox proportional
hazards models are not the most appropriate for study-
ing the evolution of breast cancer-related events occur-
ring in a patient. For a more detailed interpretation, one
should consider all events. The latter are dependent, for
example ipsilateral breast tumor recurrence may be
associated with subsequent DM and worse survival
[4,10]. A frailty model is proposed to identify the prog-
nostic factors of breast cancer recurrences, metastases
and second primary cancer among women treated by
BCS for a primary invasive breast cancer. Multiple
events in the same subject are considered so it is impor-
tant to control for the correlation of recurrent events of
different types. The frailty model is suitable for studying
these recurrent events and prevents biased inferences
[11]. In cancer studies, population heterogeneity can be
particularly important because of different exposures to
carcinogens, different genetic predispositions [12] and
the considerably varying speed with which the disease
evolves. This population variability will be expressed by
some women remaining free of recurrences throughout
follow-up and by others having frequent events. Such
frailty models could identify the risk of metastases and
the need for an adjuvant systemic treatment after a local
recurrence. By examining the association between var-
ious breast cancer-related events, it may be possible to
develop preventive interventions. Furthermore, the sta-
tistical power is increased when all available outcomes
are considered together instead of using separate statisti-
cal analyses for each subsequent outcome.
Methods
Patient characteristics and events
All female patients with a primary invasive breast cancer
and treated with BCS in a regional comprehensive
cancer center (South-West France) from 1990 to 1994
and followed up to January 2006 (n = 1015) were pro-
spectively included in a clinical and pathological data-
base [13,14]. Follow-up included a routine quarterly visit
for 2 years, every 6 months for the next 4 years and
annually thereafter [13]. Other visits could take place if
necessary. If present, a recurrence could be detected at
each visit. Patients with bilateral disease (n = 25, left
and right breasts with cancer) and patients with past
h i s t o r yo fb r e a s tc a n c e r( n=7 1 )w e r ee x c l u d e df r o m
the study (no data on the first tumor were available).
Final analyses were based on 919 women.
Up to five non-independent events could be observed
for the same patient and were of interest: a locoregional
recurrence (LRR), a contralateral cancer (in the opposite
breast), distant metastases, other primary cancer than
breast, and breast cancer death. An LRR was defined as
any recurrence of cancer in the ipsilateral breast or
chest wall or regional lymph nodes including the axil-
lary, supra/infraclavicular and internal mammary nodes.
The analyses were adjusted non-parametrically for age,
ie., age was chosen as the basic timescale. This allows to
take into account an important risk factor of recurrence,
without making parametric assumptions about the effect
of this variable. A subject was considered at risk for the
k
th failure from her age at the k-1
th failure to her age at
the k
th failure or her age of censorship. The following
prognostic factors were analyzed in the multivariate
context: lymphadenectomy (yes/no); initial treatment
combination; clinical tumor size; histological tumor size;
tumor stage (TNM classification); tumor grade (in 3
categories), histological type ((1) infiltrating ductal, (2)
infiltrating ductal with extensive intraductal component
(> 80%), (3) infiltrating lobular (including mixed types),
and (4) other types (i.e., medullary, colloid, and tubular
carcinomas); surgical excision margin status; node invol-
vement; estrogen receptor status; progesterone receptor
status; lympho-vascular invasion. Demographic features
were collected and analyzed: family history of cancer or
breast disease, parity.
Ethical approval from the national ethics committee
(Commission Nationale de l’Informatique et des Liber-
tés) was obtained for this study, which allowed the use
of data recorded in this clinical and pathological data-
base. In this comprehensive cancer center, each patient
was informed that medical data can be use in observa-
tional research. The procedure follows the French law
for medical research.
Statistical methods
In the first analysis the five outcomes of interest were
analyzed separately using a Cox proportional hazard
model [15]. Age was taken as the basic time scale in
the analysis, so the risk of recurrence was adjusted
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Page 2 of 12non-parametrically for age. This has two implications:
firstly, it enables inferences on the effects of prognostic
factors to be made without making parametric assump-
tions about the effects of age and secondly, the hazard
functions are the age-specific incidences. A subject was
considered at risk from her age at surgery to her age
at censorship or age at outcome. A Cox proportional
hazard model with delayed entry (left truncation) was
performed to estimate relative risks (RR) and to adjust
for covariates [16]. It considers that women are at risk
for an observable recurrence only after their age of
surgery, and not from birth. The recurrence hazards
functions will be represented according to age or to
the time since surgery. Patients with no failure and
lost to follow-up, alive at the study termination date
(May 31
st 2006) or who had died were censored at
their last known follow-up time for either event of
interest.
In a second analysis, all outcome types by subject were
analyzed together using a random-effects survival model
[17]. This type of model incorporates the two features
of recurrent event processes: heterogeneity among indi-
viduals and event dependence. This produces correla-
tions between recurrences. Heterogeneity is produced
b e c a u s es o m es u b j e c t sh a v eah i g h e r( o rl o w e r )e v e n t
rate than other subjects due to unknown or nonmeasur-
able effects. The frailty term (its variance) takes into
account these genetic, hormonal or environmental fac-
tors which can lead to a positive association between
our five events of interest. Further, the occurrence of a
given event may make further relapses more or less
likely. This event dependence may be acquired or
defined by biological characteristics and may be mod-
eled using time-dependent covariates. We adjusted for
the number of prior events as categorized variables (3
binary variables for 4 classes). This frailty model also
better reflects the true clinical course of the disease in
this heterogeneous population (see the “Statistical
Appendix” section). As a result, analyses that fail to
account for the correlation between survival times for
each subject are likely to underestimate the variances of
the parameters.
In all analyses, tests were two-sided and evidence was
considered to be statistically significant at the 5% level.
Individual characteristics were selected based on des-
cending stepwise multiple regressions. Analyses were
conducted using SAS software, version 9.1 (SAS Insti-
tute, INC., Cary, North Carolina). The frailty models
were implemented with the R package “frailty pack”
(publicly available and free to download at http://cran.
r-project.org).
Table 1 Patient characteristics and event distribution in
relation to patient, clinical, tumor and treatment factors
Characteristic No. of patients
Age, y
[29-39] 52 (5.7%)
[40-49] 227(24.7%)
[50-69] 512(55.7%)
≥ 70 128(13.9%)
Total 919
Histological size of the tumor (mm)
25
th quartile 11.0
Median 15.0
75
th quartile 20.0
Range 1-45
Total 881
Extensive intraductal component (EIC)
-No 866 (94.2%)
-Yes 53 (5.8%)
Total 919
Grade
- Grade 1 324 (40.0%)
- Grade 2 355 (43.8%)
- Grade 3 131 (16.2%)
Total 810
# positive nodes
- 0 549 (62.8%)
- 1-3 247 (28.3%)
- ≥4 78 (8.9%)
Total 874
Lympho-vascular invasion
- No 667 (75.8%)
- Yes 213 (24.2%)
Total 880
Surgical excision margin status
- Clear (ref) 549 (63.7%)
- Invasion 313 (36.3%)
Total 862
Progesterone receptor status
- Positive 459 (55.0%)
- Negative 376 (45.0%)
Total 835
Estrogen receptor status
- Positive 657 (21.5%)
- Negative 180 (78.5%)
Total 837
Treatment combination
- Radiotherapy 586 (63.8%)
- Radio- and chemotherapy 129 (14.1%)
- Radio- and hormonal therapy 183 (19.9%)
- Radio- and chemo- and hormonal therapy 20 (2.2%)
Total 918
Rondeau et al. BMC Cancer 2010, 10:697
http://www.biomedcentral.com/1471-2407/10/697
Page 3 of 12Results
Patient characteristics are described in Table 1. Median
age was 57 years (29 years to 87 years, mean 56.7). Axil-
lary node dissection has been performed in 882 cases
(96.0%). Surgery was followed by post-operative breast
irradiation in 913 cases (99.4%). Adjuvant therapy with
chemotherapy and/or endocrine treatments were pre-
scribed according to the menopausal status of the
patient, nodal status and hormone receptor results.
Median follow-up was 12.7 years (150 days to 16
years, mean: 11.8 years). Over the five non-independent
events studied, we observed 150 locoregional recur-
rences, 69 contralateral cancers, 188 distant metastases,
30 other primary cancers than breast, and 133 breast
cancer deaths. During the follow-up 580 (63.1%) patients
did not experience any event of interest (Table 2). At
the end of the study, 209 patients (22.7%) had died and
2 (0.2%) were lost to follow-up. The last line in Table 2
shows that the duration between two successive events
decreased with follow-up time. The median age at
entrance (53.0 years vs. 71.5 years) was lower for those
who had died from their breast cancer (n = 133) com-
pared to those who had died from other causes (n = 76).
The number of events ranged from 0 to 4 (average =
0.62) per patient. The first failure type was mostly LRR
(n = 134, 14.6%). Second failures were most commonly
death from breast cancer (n = 76, 22.4%) for all first failure
types. The most frequent event observed over the whole
follow-up was metastases, which was observed in 188 of
the women (13.9% of the total number of events observed).
Analysis of each event separately
The results of the five separate analyses for each event
of interest are shown in Table 3.
They suggest that the risk of LRR was higher for
women with higher tumor grade, with an extensive
intraductal component or with nodal invasion. In
patients treated with a combination of radiotherapy,
chemotherapy and hormonotherapy, less locoregional
occurrences were observed.
The risk of contralateral breast cancer was increased
in patients showing involvement of excision margins
after BCS (RR = 2.36, 95%CI = 1.40-3.98). By contrast,
lympho-vascular invasion was inversely associated with
contralateral breast cancer.
With regard to factors influencing distant metastases,
it was found that grade, nodal invasion and lymphovas-
cular invasion were highly prognostic factors of distant
metastases. In patients treated with a combination of
radiotherapy, chemotherapy and hormonotherapy less
metastases were observed.
No predictive factors except the progesterone receptor
status were associated with the risk of developing a new
second primary cancer other than breast carcinoma, but
a poor statistical power may explain these results (only
30 new second primary cancers were observed).
Grade and number of positive nodes were also asso-
ciated with breast cancer death. Progesterone receptor
positivity decreased the risk of death from breast cancer.
The following factors were not associated with any of
the five events of interest and were not retained in ana-
lyses in Table 3 and 4: histological type, family history of
cancer or breast disease, parity, estrogen receptor status.
Figures 1 and 2 show the baseline recurrence hazards
generated from adjusted models, according to the rank of
the recurrence or the type of the recurrence. Figure 1a
shows that the first two baseline age-specific recurrence
hazards are higher for young women (less than 40 years
Table 2 Mean follow-up times in years between two successive events (gap times) according to the type of event:
locoregional, contralateral breast cancer, metastases, 2nd cancer other than breast or breast cancer death
Event of interest Entry-first event 1
st -2
nd event 2nd - 3rd event 3rd - 4th event ANY EVENT after surgery
Gap time*
(SD)
N
(%)
Gap time
(SD)
N
(%)
Gap time
(SD)
N
(%)
Gap time
(SD)
N
(%)
Gap time
(SD)
N
(%)
Locoregional 5.85
(3.60)
134
(14.6%)
2.57
(2.13)
15
(4.4%)
7.52
-
1
(1.1%)
-
-
0
(0%)
5.53
(3.60)
150
(11.1%)
Contralateral
breast cancer
5.60
(3.45)
63
(6.9%)
1.39
(1.54)
6
(1.8%)
-
-
0
(0%)
-
-
0
(0%)
5.23
(3.53)
69
(5.1%)
Metastases 5.23
(3.29)
117
(12.7%)
1.14
(1.68)
64
(18.9%)
1.10
(1.48)
7
(7.9%)
-
-
0
(0%)
3.68
(3.42)
188
(13.9%)
2
nd cancer other than breast 4.71
(2.64)
25
(2.7%)
0.75
(0.71)
3
(0.9%)
1.71
(2.42)
2
(2.3%)
-
-
0
(0%)
4.12
(2.80)
30
(2.2%)
Death from cancer 1.56
(.)
1
(0.1%)
2.14
(1.81)
76
(22.4%)
1.83
(1.62)
52
(59.1%)
1.21
(1.97)
4
(40%)
1.99
(1.71)
133
(9.8%)
Censoring** 10.83
(2.31)
580
(63.1%)
3.41
(3.08)
251
(74.0%)
2.38
(2.20)
78
(88.6%)
1.47
(1.37)
10
(100%)
7.99
(4.51)
919
(67.8%)
TOTAL 8.87
(3.78)
919
(100%)
2.89
(2.94)
339
(100%)
2.32
(2.22)
88
(100%)
1.47
(1.37)
10
(100%)
6.89
(4.51)
1356
(100%)
* Gap time = time between two events
** censoring by death from other causes or lost to follow-up or alive at study termination
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Page 4 of 12old). It also shows that at any age the risk of failure (recur-
rence, contralateral breast cancer, metastases, 2nd primary
other than breast or death) increased successively with the
number of prior events. For instance, the risk of developing
a third event if a patient had already developed a second
event was higher than the risk of developing a second event
if she had already developed a first event. Figure 1b illus-
trates the four separate time-specific recurrence hazards
and shows that the risk of developing a first relapse event is
fairly stable across time since surgery. The time to first
event is longer than the other gap times (i.e. time between
two successive events) and can therefore occur at an older
age.
Figures 2a and 2b show the 5 type-specific hazards
(for recurrence, contralateral breast cancer, metastases,
2
nd cancer other than breast or death from breast can-
cer) without taking into account the rank of failure. The
different types of events follow different patterns across
the time intervals. The risks of developing LRR or DM
is higher than the risks of developing other events at
Table 3 Results of the 5 separate Cox regression analyses to evaluate the prognostic factors associated with the risk
of locoregional recurrence, contralateral breast cancer, metastases or 2nd cancer other than breast
Characteristic Locoregional
recurrences
Contralateral
breast cancer
Distant metastases 2
nd primary
cancer other
than breast
Breast cancer
death
RR
(95% CI)
pR R
(95% CI)
PR R
(95% CI)
PR R
(95% CI)
pR R
(95% CI)
p
Histological size of the
tumor (for 1 mm increase)
1.02
(0.99-1.06)
0.17 1.02
(0.97-1.06)
0.54 1.02
(1.00-1.05)
0.08 1.01
(0.93-1.10)
0.75 1.02
(0.99-1.05)
0.27
Extensive intraductal component (EIC)
- No (ref) 1 1 1 – 1
- Yes 3.34
(0.89-12.5)
0.07 0.99
(0.13-7.46)
1.00 1.55
(0.34-7.06)
0.57 –– 1.43
(0.20-10.8)
0.73
Grade
- Grade1(ref) 1 11 1 1
- Grade 2 1.84
(1.11-3.07)
0.02 1.45
(0.78-2.70)
0.24 2.68
(1.58-4.53)
< 0.001 0.68
(0.23-2.01)
0.48 3.64
(1.74-7.60)
< 0.001
- Grade 3 2.12
(1.17-3.84)
0.01 0.94
(0.40-2.21)
0.88 3.39
(1.91-6.02)
< 0.001 1.32
(0.37-4.75)
0.67 5.54
(2.58-11.9)
< 0.001
# positive nodes
- 0 (ref) 1 1 1 – 1
- 1-3 2.60
(1.30-5.19)
0.007 1.17
(0.34-3.97)
0.81 2.41
(1.29-4.47)
0.006 –– 2.92
(1.50-5.68)
0.002
- ≥4 4.40
(1.80-10.7)
0.001 0.66
(0.13-3.45)
0.62 6.91
(3.41-14.0)
< 0.001 –– 8.03
(3.71-17.4)
< 0.001
Lympho-vascular invasion
- No (ref) 1 11 11
- Yes 1.29
(0.84-1.98)
0.24 0.41
(0.19-0.90)
0.03 1.47
(1.04-2.08)
0.03 1.40
(0.51-3.83)
0.51 1.27
(0.87-1.91)
0.26
Surgical excision margin status
- Clear (ref) 1 1 11 1
- Invasion 0.95
(0.64-1.43)
0.81 2.36
(1.40-3.98)
0.001 1.05
(0.74-1.48)
0.78 0.57
(0.19-1.73)
0.32 1.12
(0.75-1.67)
0.59
Progesterone receptor status
-Positive(ref) 1 1 1 1 1
- Negative 1.26
(0.84-1.88)
0.26 1.21
(0.70-2.09)
0.49 1.32
(0.93-1.86)
0.12 0.33
(0.11-1.03)
0.06 1.90
(1.26-2.87)
0.002
Treatment combination
- Radiotherapy (ref) 1 11 – 1
- Radio- and chemotherapy 0.23
(0.11-0.50)
< 0.001 1.22
(0.33-4.55)
0.77 0.52
(0.27-1.02)
0.06 –– 0.56
(0.27-1.16)
0.12
- Radio- and hormonal therapy 0.35
(0.16-0.77)
0.009 0.78
(0.21-2.91)
0.71 0.59
(0.30-1.13)
0.11 –– 0.48
(0.24-0.99)
0.05
- Radio- and chemo-
and hormonal therapy
0.06
(0.01-0.49)
0.008 0.74
(0.07-7.60)
0.80 0.33
(0.11-0.99)
0.05 –– 0.28
(0.07-1.06)
0.06
– variables not included in the model
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Page 5 of 12Table 4 Results of the frailty models to evaluate jointly the prognostic factors associated with any of the 5 types of
failures: locoregional recurrence, contralateral breast cancer, metastases, 2nd cancer other than breast or breast
cancer death
Model 1 Model 2 Model 3
Characteristic* RR
(95% CI)
RR
(95% CI)
RR
(95% CI)
Histological size of the tumor (for 1 mm increase) 1.03
(1.01-1.06)
1.02
(1.00-1.04)
1.02
(1.00-1.04)
Extensive intraductal component (EIC)
- No (ref) 1 1 1
- Yes 1.91
(0.58-6.24)
1.44
(0.58-3.59)
1.21
(0.49-3.01)
Grade
- Grade 1 (ref) 11 1
- Grade 2 2.06
(1.44-2.95)
1.77
(1.30-2.40)
1.69
(1.24-2.29)
- Grade 3 3.19
(2.08-4.87)
2.41
(1.69-3.43)
2.32
(1.64-3.29)
# positive nodes
- 0 (ref) 11 1
- 1-3 2.82
(1.62-4.91)
2.33
(1.52-3.57)
2.33
(1.52-3.55)
- ≥4 6.16
(3.15-12.04)
4.60
(2.74-7.72)
3.97
(2.36-6.66)
Lympho-vascular invasion
- No (ref) 1 1 1
- Yes 1.10
(0.80-1.52)
1.08
(0.85-1.38)
1.02
(0.80-1.30)
Surgical excision margin status
- Clear (ref) 1 11
- Invasion 1.36
(1.02-1.82)
1.21
(0.96-1.52)
1.23
(0.97-1.54)
Progesterone receptor status
- Yes (ref) 11 1
-N o 1.45
(1.09-1.93)
1.43
(1.14-1.80)
1.46
(1.16-1.83)
Treatment combination
- Radiotherapy (ref) 11 1
- Radio- and chemotherapy 0.50
(0.27-0.91)
0.55
(0.35-0.87)
0.59
(0.37-0.93)
- Radio- and hormonal therapy 0.36
(0.19-0.66)
0.50
(0.31-0.81)
0.54
(0.34-0.86)
- Radio- and chemo- and hormonal therapy 0.22
(0.08-0.63)
0.29
(0.12-0.67)
0.31
(0.13-0.72)
Number of prior events
(as a quantitative variable)
- 1.97
(1.62-2.41)
0.96
(0.67-1.41)
Type of prior events:
- no previous event (ref) - - 1
- locoregional - - 4.25
(2.51-7.21)
- contralateral breast cancer - - 1.44
(0.75-2.74)
- distant metastases - - 3.94
(2.23-6.96)
-2
nd primary other than breast -
(-)
Variance of the random effect 1.42 (0.24) 0.38 (0.20) 0.35 (0.17)
Akaike Information Criterium (AIC) 1518.98 1494.10 1461.69
* Analyses parametrically adjusted for the characteristics mentioned and non-parametrically adjusted for age
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was observed during the first 10 years after surgery (see
Figure 2b) but the other types of failure occurred at a
constant rate over at least 10 years. After that time, the
risk of failure decreases progressively.
Combined analysis of all events
We analyzed the successive failures for each subject and
their dependence using a random effects analysis (Table 4,
with or without adjustment for the number of prior events
or the type of failure). The rate of failure increased with
grade (grade 2 vs. grade 1, RR = 1.77, 95% CI = 1.30-2.41;
grade 3 vs. grade 1, RR = 2.41, 95% CI = 1.69-3.43 in model
2) and was higher for women with nodal invasion and with
radiotherapy alone. The histological tumor size was asso-
ciated with the rate of failure; this association was not pre-
viously observed in the 4 separate analyses (see Table 3).
We observed a significant association between the treatment
a
b
*from models adjusted for histological tumor size, extensive intraductal component, grade,
node involvement, lympho-vascular invasion, surgical excision margin status, progesterone
receptor status, initial treatment combination
Figure 1 Age-specific* (a) and time-specific* (b) recurrence hazards after a breast cancer treated by breast-conserving surgery for the
first, second, third or fourth event.
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with decreasing risks when chemotherapy and hormonal
therapy were added to locoregional treatment.
The number of previous events (as a quantitative variable)
was significantly associated with an increased risk of failure
given the frailty term, but was no longer significant after
adjustment for the type of failure. The coding of the number
of prior events as categorical variables confirmed the above
mentioned relationships. The tendency was towards a higher
risk of second failure compared to the risk of first failure.
Heterogeneity of the survival times was observed in
model 1 (Table 4, see variance of the random effects)
a
b
*for locoregional, controlateral and distant metastases, models were adjusted for histological 
tumor size, extensive intraductal component, grade, node involvement, lympho-vascular 
invasion, surgical excision margin status, progesterone receptor status, initial treatment 
combination, age at surgery; for 2
nd primary cancer other than breast, models were adjusted 
for histological tumor size, lympho-vascular invasion, surgical excision margin status, 
progesterone receptor status
Figure 2 Age-specific* (a) and time-specific* (b) recurrence hazards after a breast cancer treated by breast-conserving surgery
according to the type of relapse.
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iance of the random effects (0.38) decreased in model 2
a f t e ra d j u s t m e n tf o rt h ep r i o rn u m b e ro fe v e n t sb u t
remained significantly different from zero. Model 3
(Table 4) shows the influence of the type of first event:
the risk of developing a new failure is greatly increased
(RR = 4.25) after developing a LRR, but also after devel-
oping DM (RR = 3.94) as compared to patients who did
not develop a first event. The small number of patients
with a second primary cancer other than breast and fol-
lowed by an event (n = 1) makes this variable estimate
unreliable.
Discussion
This study uses a novel approach of analyzing together
the different rates of failure following successive events
for women with breast cancer treated with BCS. The
risk of relapse of any type was higher for young women
(less than 40 years old) and is higher in the first 10
years after surgery. Traditionally guidelines for follow-
up of breast cancer patients concentrate on the first 3-5
years, with either reduced frequency of visits or dis-
charge after this. Montgomery et al. [18] show that the
basic assumptions behind these generally-accepted
guidelines for follow-up may be incorrect. They suggest
that if the central aim is the detection of treatable
relapse, as stated in the guidelines, then there is no jus-
tification for focusing on the first 2-3 years after initial
therapy, as treatable relapses occur at a constant rate
over at least 10 years. Our results are in accordance
with these results and the implications for cancer care
should be carefully considered.
As this was a prospective observational study in a sin-
gle center, there are potential limitations to our results.
Principal among these limitations could be a bias for
patient selection or for their follow-up. In terms of
patient selection, we noted a median age (57 years)
lower than the median age incidence in France [19] (61
years), but we selected only invasive breast cancer. The
potential bias for follow up in these types of studies
appears not to be the case in this study as the cancer
center employs a rigourous clinical follow-up procedure
and we administered a survey to physicians resulting in
less than 2% losses to follow-up [13].
This frailty model allows the analyst to estimate
simultaneously and distinctly the effects of both unob-
served heterogeneity through a subject-specific random
effect and event dependence through a time-dependent
covariate. It also helps us to diagnose the source of cor-
relation in the data by comparing the magnitude of the
estimated effects across the models, i.e. the adjustment
to some covariates will completely explain the unob-
served heterogeneity. In this typical repeated events con-
text, the usual Cox model was both biased and
inefficient and the five separate analyses were uninfor-
mative with regard to heterogeneity across individuals
and event dependence. Furthermore, the combined ana-
lysis increased the statistical power to such an extent
that the associations of some prognostic factors with
any event were revealed (ex: histological tumor size in
Table 4). No separate analysis was able to do this. Since
the risk of any recurrence was higher for young women
and in the first 10 years after surgery, this justifies the
need for increased surveillance of women in the first
years following the diagnosis of cancer. Tai et al. [20]
recently proposed a marginal approach in order to uti-
lize fully all the available information on event times
and not only the information on the first event that
occurs. But, their approach does not measure the depen-
dence among the multiple events and the influence of
p r i o re v e n t so nf u t u r ef a i l u r e si sn o tt h e i rf o c u s .
Recently using a multivariate multistate model, de Bock
et al. [21] found that patients with a LRR have a more
than threefold increased risk of developing DM as com-
pared to patients who develop no LRR. As with the
frailty model, the strongest point of their approach is
that all the data are summarized in one model instead
of presenting many separate analyses. Presenting the
many separate analyses will lower the power of the esti-
mated effects or may result in false positive findings.
However such a multistate analysis can only be
performed on a large cohort of patients with a long fol-
low-up time (with enough metastatic events after the
occurrence of LRR). The frailty model is less restrictive
on the number of events.
At the end of the study, 209 patients had died, among
them 133 had died from their breast cancer. Deaths could
be related to their health status and more specifically to
breast cancer recurrences (local or distant). Thus, breast
cancer death is likely to be an informative type of censor-
ing, which means that those individuals who are censored
by death are not as likely to have the subsequent event of
interest as those who remained in the study. In order to
examine this hypothesis we used a joint frailty model
(using the R package “frailtypack”) to analyze recurrent
observations of breast cancer with death from breast can-
cer [22,23]. For instance, a patient recurrence rate may be
positively correlated with its death rate. The effects of
prognostic factors were unchanged in this joint frailty
model. Therefore, censoring by death from breast cancer
appears to be non-informative for recurrence after adjust-
ment. This suggests that selection by death from breast
cancer in this study did not importantly bias our findings.
In this study we proposed to control for the type of
event by adjusting for this variable in the frailty models
(see Table 4, model 3). We then observed that patients
with a LRR had a more than fourfold increased risk of
developing a new event as compared to patients who
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the prognostic factors had the same effects for the dif-
ferent types of event. Another approach could be to use
a joint frailty model with one hazard function for each
type of event [24]. This would allow us to evaluate the
prognostic impact for each type of event and so for each
clinical etiology. However we have not considered this
extension in the present application, due to the
increased computational complexity of the problem.
Using breast cancer data from a population-based can-
cer registry, Cheung et al. [25] illustrated the features of
Cox models using two time scales (time since diagnosis
and age). Using time since diagnosis as the time scale, a
younger age at diagnosis was associated with a lower
mortality, while using age as the time scale gave the
opposite result. Age was chosen as the basic time scale
in our analysis, so no parametric assumptions were
made in the analyses and the hazard function of the
time of onset of any recurrence was the age-specific
incidence of the recurrence. We also analyzed parame-
trically the effect of age by introducing age as a covari-
ate in a proportional hazard model (i.e. with a log-linear
relationship). The results were quite similar in models
adjusted for age with four classes coded by three binary
variables (40-49, 50-69, 70 and over versus 29-39 years).
Age was associated with the risk of locoregional recur-
rence or metastases with a higher risk for younger
patients. However, if the true effect of age is far from
this parametric log-linear assumption, this may lead to
spurious results.
Our study seems to show a previously unreported
unexplained protective effect of lympho-vascular invasion
on the risk of contralateral breast cancer. The epidemiol-
ogy of contralateral breast cancer is complex to study for
a number of reasons. Firstly, the patient has received
treatment that may modify the risk of second cancer, and
she is under intense medical scrutiny and self-observa-
tion [26,27]. Secondly, the treatment and follow-up pro-
cedures for breast cancer have changed extensively over
the years and several definitions of contralateral breast
cancer were observed. This may contribute to the inco-
herent results reported in the epidemiology of contralat-
eral disease [27,28]. Comparison of genomic profiles
would allow differentiation between metastatic lesions
and new primary tumor, but this information was not
available to us. Microarray studies have shown that dis-
tinct molecular profiles can be useful for classifying
tumors and predicting outcome [29].
Tailored systemic treatment making use of ER and PR
receptors and HER2 is now current practice [30]. How-
ever these prognostic factors were missing in our study.
Only more recent studies will include the newer predic-
tive and prognostic factors, but these studies will not
allow us to perform such long-term analyses due to
their shorter follow-up.
Conclusions
In conclusion, the frailty model approach allows the
simultaneous analysis of all successive events intervening
after a first breast cancer. This methodology in conjunc-
tion with conventional methods represents a valuable
tool for describing the natural history of breast cancer
and the possible effects of treatment. This methodology
issue may also be relevant to studies of other tumor
types with recurrences. This approach can also, if data
require it, incorporate the effects of interventions which
are performed after each event. Response to treatment
after each relapse may be an important factor to predict
new relapses; this is an important issue which is not
considered in the models for recurrent event data.
Statistical Appendix
We consider models in which the hazard function partly
depends on an unobservable random variable thought to
act multiplicatively on the hazard, so that a large value
of the variable increases the hazard. These models,
called frailty models are an extension of the classical
Cox proportional hazard model [15].
Suppose there are N subjects in a study. For the j
th
event (j = 1,..., ni) of the i
th individual (i = 1,...,N), let Tij
denote the survival times under study and let Cij be the
corresponding right-censoring times. The observations
are Yij =m i n ( Tij, Cij) and the censoring indicator Δij = I
(Tij ≤ Cij) is one if the observation j is a failure and 0 if
it is a censoring. Our frailty model specifies that the
hazard function conditional on the frailty is:
  ij i ij i ij tZ X Z t X ( , ) ( )exp( ’ ) = 0
where l0(t) is the baseline hazard function; Xij =
(X1ij,..., Xpij)’ denotes the covariate vector for the j
th
recurrence of individual i, b is the corresponding vector
of regression parameters, and the Zi’s are unobserved
random variables (the frailties). It is assumed for mathe-
matical convenience that the Zi’s are independently and
identically distributed from a gamma distribution with
mean 1 and unknown variance θ at time of origin.
Different timescales can be used [31]. The timescale
that is most often used is the gap time: after an event,
the subject starts again at time 0 and the time to the
next event corresponds to the number of days that it
takes to experience the next event. An alternative time-
scale is the calendar time, also called the counting pro-
cess approach [32] which keeps track of time since
randomization. The duration of the time at risk for an
event corresponds to the duration of the time at risk in
Rondeau et al. BMC Cancer 2010, 10:697
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at-risk period is not reset to 0. A subject is not consid-
ered to be at risk for the k
th event until after the (k-1)
th
event. A particular subject has different periods at risk
during the total observation time. If there are ni at-risk
periods for patient i, then the complete information for
patient i can be represented by ni triplets
( , , ),...,( , , ) YY Y Y ii i i n i ni n ii i 11 12 1 1 2 ΔΔ where, for the j
th
triplet, Yij1 is the start of the j
th at-risk period, Yij2 is the
end of the j
th at-risk period, Δij is the censoring indica-
tor and Yi11 = 0. If age is chosen as the basic timescale,
the hazard functions estimated are for instance the
age-specific recurrence incidences or the age-specific
mortality. A subject is considered at risk from her age at
surgery (= Yi11) to her age at censorship or failure.
The expression of the full marginal likelihood asso-
ciated with this frailty model is used. In most situations it
is reasonable to expect smooth baseline hazard functions,
piecewise constant modeling for the hazard functions
often being unrealistic. To introduce such a priori knowl-
edge, we penalize the likelihood. The expression of the
full marginal likelihood is developed in expression 4 of
Rondeau et al. [23].
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